Poland · Delayed Price · Currency is PLN Celon Pharma Statistics
Total Valuation
Celon Pharma has a market cap or net worth of PLN 1.07 billion. The enterprise value is 1.11 billion.
| Market Cap | 1.07B |
| Enterprise Value | 1.11B |
Important Dates
The next confirmed earnings date is Wednesday, September 16, 2026.
| Earnings Date | Sep 16, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Celon Pharma has 53.86 million shares outstanding. The number of shares has increased by 0.43% in one year.
| Current Share Class | 38.86M |
| Shares Outstanding | 53.86M |
| Shares Change (YoY) | +0.43% |
| Shares Change (QoQ) | -0.99% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 17.98% |
| Float | 23.82M |
Valuation Ratios
The trailing PE ratio is 9.74 and the forward PE ratio is 322.81.
| PE Ratio | 9.74 |
| Forward PE | 322.81 |
| PS Ratio | 4.15 |
| PB Ratio | 2.01 |
| P/TBV Ratio | 2.10 |
| P/FCF Ratio | 53.73 |
| P/OCF Ratio | 34.96 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 39.33, with an EV/FCF ratio of 55.98.
| EV / Earnings | 10.25 |
| EV / Sales | 4.33 |
| EV / EBITDA | 39.33 |
| EV / EBIT | n/a |
| EV / FCF | 55.98 |
Financial Position
The company has a current ratio of 1.20, with a Debt / Equity ratio of 0.10.
| Current Ratio | 1.20 |
| Quick Ratio | 0.87 |
| Debt / Equity | 0.10 |
| Debt / EBITDA | 2.06 |
| Debt / FCF | 2.71 |
| Interest Coverage | -332.58 |
Financial Efficiency
Return on equity (ROE) is 22.84% and return on invested capital (ROIC) is -2.19%.
| Return on Equity (ROE) | 22.84% |
| Return on Assets (ROA) | -1.26% |
| Return on Invested Capital (ROIC) | -2.19% |
| Return on Capital Employed (ROCE) | -2.05% |
| Weighted Average Cost of Capital (WACC) | 7.55% |
| Revenue Per Employee | 454,863 |
| Profits Per Employee | 192,055 |
| Employee Count | 564 |
| Asset Turnover | 0.43 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Celon Pharma has paid 15.56 million in taxes.
| Income Tax | 15.56M |
| Effective Tax Rate | 12.56% |
Stock Price Statistics
The stock price has decreased by -12.09% in the last 52 weeks. The beta is 0.67, so Celon Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.67 |
| 52-Week Price Change | -12.09% |
| 50-Day Moving Average | 20.71 |
| 200-Day Moving Average | 21.25 |
| Relative Strength Index (RSI) | 37.92 |
| Average Volume (20 Days) | 10,085 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Celon Pharma had revenue of PLN 256.54 million and earned 108.32 million in profits. Earnings per share was 2.03.
| Revenue | 256.54M |
| Gross Profit | 259.13M |
| Operating Income | -11.97M |
| Pretax Income | 123.88M |
| Net Income | 108.32M |
| EBITDA | 19.19M |
| EBIT | -11.97M |
| Earnings Per Share (EPS) | 2.03 |
Balance Sheet
The company has 9.09 million in cash and 53.68 million in debt, with a net cash position of -44.58 million or -0.83 per share.
| Cash & Cash Equivalents | 9.09M |
| Total Debt | 53.68M |
| Net Cash | -44.58M |
| Net Cash Per Share | -0.83 |
| Equity (Book Value) | 528.78M |
| Book Value Per Share | 9.82 |
| Working Capital | 17.85M |
Cash Flow
In the last 12 months, operating cash flow was 30.47 million and capital expenditures -10.65 million, giving a free cash flow of 19.83 million.
| Operating Cash Flow | 30.47M |
| Capital Expenditures | -10.65M |
| Depreciation & Amortization | 31.16M |
| Net Borrowing | 7.50M |
| Free Cash Flow | 19.83M |
| FCF Per Share | 0.37 |
Margins
Gross margin is 101.01%, with operating and profit margins of -4.67% and 42.22%.
| Gross Margin | 101.01% |
| Operating Margin | -4.67% |
| Pretax Margin | 48.29% |
| Profit Margin | 42.22% |
| EBITDA Margin | 7.48% |
| EBIT Margin | -4.67% |
| FCF Margin | 7.73% |
Dividends & Yields
Celon Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.43% |
| Shareholder Yield | -0.43% |
| Earnings Yield | 10.17% |
| FCF Yield | 1.86% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside |
Analyst Forecast
The average price target for Celon Pharma is 20.44, which is 4.07% higher than the current price. The consensus rating is "Hold".
| Price Target | 20.44 |
| Price Target Difference | 4.07% |
| Analyst Consensus | Hold |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | 9.07% |
| EPS Growth Forecast (3Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Celon Pharma has an Altman Z-Score of 5.45 and a Piotroski F-Score of 4.
| Altman Z-Score | 5.45 |
| Piotroski F-Score | 4 |